BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
BioArctic Partners With Bristol Myers Squibb In Licensing Deal For PyroGlutamate-Amyloid-Beta Antibody Program
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE:BMY) for BioArctic's PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic's BrainTransporter technology. As part of the agreement, BioArctic will receive a USD 100 million upfront payment and up to USD 1.25 billion in milestone payments. BioArctic is also entitled to tiered low double-digit royalties on global product sales.
BioArctic Ab（公衆）(納斯達克斯德哥爾摩：BIOA B)今天宣佈與百時美施貴寶（紐交所：BMY）簽訂了一項全球獨佔許可協議，涉及BioArctic的PyroGlutamate-澱粉樣β (PyroGlu-Aβ) 抗體項目，包括BAN1503和BAN2803，其中後者包括BioArctic的BrainTransporter技術。作爲協議的一部分，BioArctic將獲得10000萬美元的首付款以及高達12.5億美金的里程碑付款。BioArctic還將享有全球產品銷售的分級低雙位數版權。
譯文內容由第三人軟體翻譯。
